cobas EZH2 Mutation Test
Roche Molecular System, Inc. · Decision date Jun 18, 2020
What did the FDA decide?
The FDA approved the cobas EZH2 Mutation Test, a real-time allele-specific PCR test for qualitative detection of specific single nucleotide mutations in the EZH2 gene. The detected mutations are Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V, using DNA extracted from formalin fixed paraffin embedded human follicular lymphoma tumor tissue specimens.
The test is intended to identify follicular lymphoma patients with an EZH2 mutation for treatment with TAZVERIK (tazemetostat), in accordance with the approved therapeutic product labeling. The statement reports this intended identification purpose but does not independently establish safety or clinical effectiveness. The applicant is Roche Molecular System, Inc., and the product code is OWD.
FDA approval order statement
Approval for The cobas EZH2 Mutation Test. The device is a real-time allele-specific PCR test for qualitative detection of single nucleotide mutations for Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene in DNA extracted from formalin fixed paraffin embedded (FFPE) human follicular lymphoma tumor tissue specimens. The cobas EZH2 Mutation Test is intended for the identification of follicular lymphoma patients with an EZH2 mutation for treatment with TAZVERIK (tazemetostat), in accordance with the approved therapeutic product labeling.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Jun 18, 2020
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200014
- Regulatory pathway
- Premarket approval application
- Applicant
- Roche Molecular System, Inc.
- Product code
- OWD
- Decision code
- APWD
- Decision date
- Jun 18, 2020
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
- Applicant
- Roche Molecular System, Inc.
- Product code
- OWD
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P200014 received
Application receipt date recorded by FDA.
P200014 · FDA decision
APWD
P200014/S012 · Related supplement
cobas EZH2 Mutation Test
Timeline entries are records held by MedtechLedger for P200014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas EZH2 Mutation TestP200014/S012 | Roche Molecular System, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular System, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P200014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



